← Back to Search

Cancer Vaccine

Vaccine Therapy for Melanoma

Phase 1

Waitlist Available

Research Sponsored by Baylor Health Care System

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Immunologic: No active infection

Performance status: Karnofsky 80-100%

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a vaccine made from a patient's white blood cells and mixed with tumor antigens. The purpose is to study if this can help the body build an immune response to kill tumor cells in patients with metastatic melanoma.

Who is the study for?

This trial is for adults over 21 with metastatic melanoma, a specific skin cancer. They must have a certain immune system marker (HLA-A2-01), measurable disease, and be generally healthy without active brain or liver cancer spread. Participants need to react to common skin tests, not have HIV, and use contraception if fertile.Check my eligibility

What is being tested?

The study is testing a vaccine therapy made from the patient's own white blood cells combined with tumor antigens. The goal is to see if this can stimulate the body's immune response to destroy cancer cells in patients with advanced melanoma.See study design

What are the potential side effects?

Potential side effects are not detailed here but may include typical reactions related to vaccines such as soreness at injection site, fever, fatigue or allergic responses given that it involves the body’s immune system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have any current infections.

Select...

I am mostly self-sufficient and active.

Select...

I do not have cancer spread to my brain or liver.

Select...

I am 21 years old or older.

Select...

I have never had an autoimmune disease like lupus, rheumatoid arthritis, or thyroiditis.

Select...

My cancer can be measured by tests.

Select...

My melanoma has spread and this was confirmed through a biopsy.

Select...

I have the HLA-A2-01 genetic trait.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 8Eligibility criteria met

Find a Location

Who is running the clinical trial?

Baylor Health Care SystemLead Sponsor

17 Previous Clinical Trials

18,842 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,153 Total Patients Enrolled

Joseph W. Fay, MDStudy ChairBaylor Health Care System

2 Previous Clinical Trials

41 Total Patients Enrolled

Media Library

Vaccine Therapy (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00017355 — Phase 1

Skin Cancer Clinical Trial 2023: Vaccine Therapy Highlights & Side Effects. Trial Name: NCT00017355 — Phase 1

Vaccine Therapy (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00017355 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What safety measures have been put in place to ensure the efficacy of this remedy?

"Due to the Phase 1 nature of this trial, our team's assessment of its safety was a score of 1 as there is limited evidence supporting efficacy and safety."

Answered by AI

Are there any vacancies in this research experiment for volunteer participants?

"According to clinicaltrials.gov, this particular medical trial is not enlisting participants at the moment. It was first announced in April 2001 and its most recent update occurred on September 16th 2013; however, there are currently 757 other trials that are actively recruiting new patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vaccine Therapy in Treating Patients With Metastatic Melanoma

2001. "Vaccine Therapy in Treating Patients With Metastatic Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00017355.

All > Ic